Egypt Recalls ‍Popular ⁢Cough Syrup Amidst Quality Concerns

In a important development impacting⁤ public⁣ health in Egypt, the Egyptian Medicines Authority⁢ (EMA) has announced ‌a second recall this year of Tussinor syrup, a widely used cough suppressant and expectorant.The recall, affecting a specific batch of the​ medication, ⁤highlights the EMA’s commitment to ensuring the quality and safety ⁢of pharmaceuticals available to Egyptian citizens.

the EMA’s statement cited non-compliance with established quality standards as the reason⁣ for the ⁢recall. This ⁤isn’t the first time Tussinor has faced scrutiny; a previous recall occurred earlier in 2024, ​involving multiple batches of the product. This latest action underscores the EMA’s proactive approach to addressing potential risks to public ⁣health.

Tussinor syrup is commonly used to alleviate‍ coughs⁢ and loosen phlegm associated with common illnesses ​like ​colds ⁢and the flu. ‌ The ​EMA emphasized ‍that the recall onyl applies to the specific batch identified in their official declaration ⁤(batch number ​M2028823) and does not affect all Tussinor syrup ​currently in circulation.

The impact of the recall is considerable. According to the IQ ​Via Foundation, a market research ⁣firm specializing in‍ the Egyptian pharmaceutical sector, ⁢sales ⁤of Tussinor syrup exceeded 149,000 packages in the first nine months of‍ 2024, representing ‍a significant financial value exceeding 5⁤ million Egyptian pounds.

The EMA urged consumers​ to ⁤exercise caution and ⁢vigilance. “In ⁢case of doubt ‍about any medicinal readiness,refer to the pharmacist to​ verify the packaging or call‍ the hotline,” the EMA ⁤advised,emphasizing‌ that these actions are taken to ⁢protect public health and align ‌with global standards set by the World Health Organization.

This situation mirrors similar challenges⁢ faced by regulatory bodies worldwide in ensuring the ⁢quality and safety of medications. ‍ The EMA’s‌ swift action serves as a reminder of the importance of robust quality control measures within⁤ the pharmaceutical industry and the ​ongoing efforts to protect consumers from possibly harmful products.

The Egyptian Medicines Authority (EMA) issued a ‍second recall this year for a specific batch (batch number ​M2028823) of ⁤Tussinor syrup, a popular ⁢cough suppressant and‍ expectorant.⁢ [1] [2]



The ⁢recall was triggered by⁢ the EMA’s revelation that⁣ this‌ particular batch did not meet the required quality standards. ‌ [1] [2] this follows an earlier recall in 2024 that involved multiple batches. ⁢ [1]





The EMA emphasized that this recall only applies to the⁤ specified⁢ batch and does not ​affect ⁣all⁤ Tussinor syrup products.​ [1]



Tussinor syrup is‌ a widely used treatment for coughs and phlegm associated with colds and flu.



The recall has notable implications, as Tussinor syrup is a popular medication with sales ​exceeding 149,000 packages ⁣in ⁢the first nine‌ months of 2024,​ amounting to a​ value of​ over 5 million Egyptian pounds. [1]



The EMA⁤ advises consumers to be cautious and, if uncertain about any medication, consult a pharmacist or their hotline to ⁤verify ‍the product’s⁣ packaging and authenticity.







[1][2]